We are live on ! Find out more
RDY icon

Dr. Reddy's Laboratories

161 hedge funds and large institutions have $805M invested in Dr. Reddy's Laboratories in 2022 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 60 increasing their positions, 39 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

840% more call options, than puts

Call options by funds: $47K | Put options by funds: $5K

88% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 17

54% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 39

7% more funds holding

Funds holding: 150161 (+11)

0.2% more ownership

Funds ownership: 49.11%49.31% (+0.2%)

4% less capital invested

Capital invested by funds: $840M → $805M (-$35.5M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
161
Holders Change
+11
Holders Change %
+7.33%
% of All Funds
2.59%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
32
Increased
60
Reduced
39
Closed
17
Calls
$47K
Puts
$5K
Net Calls
+$42K
Net Calls Change
+$37K
Name Holding Trade Value Shares
Change
Change in
Stake
PA
126
Parallel Advisors
California
$159K -$134K -12,430 -45%
AG
127
AIA Group
Hong Kong
$152K +$159K +14,725 New
JWM
128
Janiczek Wealth Management
Colorado
$149K +$10.9K +1,010 +8%
LC
129
Lindbrook Capital
California
$144K +$26.1K +2,415 +21%
DGAM
130
Desjardins Global Asset Management
Quebec, Canada
$137K
MIFH
131
Migdal Insurance & Financial Holdings
Israel
$104K
BTI
132
Blue Trust Inc
Georgia
$73K +$22.8K +2,115 +43%
SC
133
Seldon Capital
California
$71.9K
Carson Wealth (CWM LLC)
134
Carson Wealth (CWM LLC)
Nebraska
$59K +$11.9K +1,105 +24%
Wells Fargo
135
Wells Fargo
California
$57.3K -$4.05K -375 -6%
Osaic Holdings
136
Osaic Holdings
Arizona
$47.1K -$58.4K -5,410 -54%
Dimensional Fund Advisors
137
Dimensional Fund Advisors
Texas
$45.1K +$1.88M +174,245 +4%
AssetMark Inc
138
AssetMark Inc
California
$37.8K -$4.1K -380 -9%
DekaBank Deutsche Girozentrale
139
DekaBank Deutsche Girozentrale
Germany
$36K
JIR
140
James Investment Research
Ohio
$29K +$30.3K +2,805 New
GJIA
141
Glass Jacobson Investment Advisors
Maryland
$20.7K +$21.6K +2,000 New
TRCT
142
Tower Research Capital (TRC)
New York
$20K +$1.56K +145 +8%
EWA
143
EverSource Wealth Advisors
Alabama
$19K -$1.67K -155 -8%
AF
144
Allworth Financial
California
$17.1K +$4.96K +460 +38%
First Manhattan
145
First Manhattan
New York
$15.9K +$16.6K +1,540 New
GWS
146
Glassman Wealth Services
Virginia
$14.5K +$5.34K +495 +54%
GKIM
147
GW&K Investment Management
Massachusetts
$11K
3IP
148
3Chopt Investment Partners
Virginia
$10.3K +$10.8K +1,000 New
LFG
149
Larson Financial Group
Missouri
$7.54K
VanEck Associates
150
VanEck Associates
New York
$7K +$2.75K +255 +67%

RDY Hedge Fund Activity: Q4 2022 in Review

161 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q4 2022, worth a combined $805M — down 4.2% from $840M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new RDY positions and 17 closed out — a net gain of 15 holders — while 60 added to existing stakes and 39 trimmed.

The largest buyer was Robeco Institutional Asset Management, opening a new position worth an estimated $47.6M. The largest seller was Morgan Stanley, cutting an estimated $27.4M.

  • 161 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q4 2022, up from 150 in Q3 2022.
  • Funds reported $805M of Dr. Reddy's Laboratories stock for Q4 2022, down 4.2% quarter-over-quarter.
  • 32 funds opened new Dr. Reddy's Laboratories positions in Q4 2022 and 17 closed out, a net change of +15 holders.
  • The largest Dr. Reddy's Laboratories buyer in Q4 2022 was Robeco Institutional Asset Management, an estimated $47.6M added.
  • The largest Dr. Reddy's Laboratories seller in Q4 2022 was Morgan Stanley, an estimated $27.4M sold.

Based on aggregated 13F filings for Q4 2022.